par Durbecq, Virginie ;Ameye, Lieveke;Veys, Isabelle ;Paesmans, Marianne ;Desmedt, Christine ;Sirtaine, N.;Sotiriou, Christos ;Bernard, Chantal ;Nogaret, Jean-Marie ;Piccart-Gebhart, Martine ;Larsimont, Denis
Référence Critical reviews in oncology/hematology, 67, 1, page (80-92)
Publication Publié, 2008-07
Référence Critical reviews in oncology/hematology, 67, 1, page (80-92)
Publication Publié, 2008-07
Article révisé par les pairs
Résumé : | INTRODUCTION: To investigate the influence of ageing on the incidence of breast cancer (BC) molecular subtypes, patient age at diagnosis was correlated with bio-pathological data collected retrospectively from 2723 consecutive patients diagnosed/treated at our Institute between 2000 and 2003. METHODS: According to their bio-characteristics, 61% of the samples could be assigned to a molecular subtype: the "HER-2+", the "ER & HER2 negative" or one of the two "luminal-like" subtypes divided according to their histological grade ("A" [HER-2-/ER+/grade 1-2] and "B" [HER-2-/ER+/grade 3]). RESULTS AND CONCLUSION: Age is highly influencing the incidence of BC molecular subtypes. Patients younger than 40 develop a statistically higher rate of high grade proliferating "HER-2" (27%) and "ER & HER2 negative" (31%) BC whereas patients older than 50 develop mostly less aggressive hormone-dependant "luminal-A" BC (>67%). Nevertheless, a significant proportion of patients older than 70 develop "luminal-B" (19%) tumours associated with high proliferation, high grade, large size and nodal invasion. |